دورية أكاديمية
أعرض في EDS

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma.

التفاصيل البيبلوغرافية
العنوان: Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma.
المؤلفون: Creaney J; National Centre for Asbestos Related Disease, Medical School, University of Western Australia, Level 5, QQ Block, QEII Medical Centre, 6 Verdun Street, Nedlands, WA, 6009, Australia.; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.; Centre for Respiratory Health, University of Western Australia, Nedlands, WA, Australia., Patch AM; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia.; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia., Addala V; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia.; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia., Sneddon SA; National Centre for Asbestos Related Disease, Medical School, University of Western Australia, Level 5, QQ Block, QEII Medical Centre, 6 Verdun Street, Nedlands, WA, 6009, Australia., Nones K; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Dick IM; National Centre for Asbestos Related Disease, Medical School, University of Western Australia, Level 5, QQ Block, QEII Medical Centre, 6 Verdun Street, Nedlands, WA, 6009, Australia.; Centre for Respiratory Health, University of Western Australia, Nedlands, WA, Australia., Lee YCG; National Centre for Asbestos Related Disease, Medical School, University of Western Australia, Level 5, QQ Block, QEII Medical Centre, 6 Verdun Street, Nedlands, WA, 6009, Australia.; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.; Centre for Respiratory Health, University of Western Australia, Nedlands, WA, Australia., Newell F; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Rouse EJ; National Centre for Asbestos Related Disease, Medical School, University of Western Australia, Level 5, QQ Block, QEII Medical Centre, 6 Verdun Street, Nedlands, WA, 6009, Australia.; Centre for Respiratory Health, University of Western Australia, Nedlands, WA, Australia., Naeini MM; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Kondrashova O; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Lakis V; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Nakas A; Cancer Research UK Centre Leicester, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK., Waller D; Cancer Research UK Centre Leicester, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK., Sharkey A; Cancer Research UK Centre Leicester, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK., Mukhopadhyay P; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Kazakoff SH; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Koufariotis LT; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Davidson AL; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia.; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia., Ramarao-Milne P; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Holmes O; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Xu Q; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Leonard C; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Wood S; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Grimmond SM; University of Melbourne Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Bueno R; Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA., Fennell DA; Cancer Research UK Centre Leicester, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK., Pearson JV; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., Robinson BW; National Centre for Asbestos Related Disease, Medical School, University of Western Australia, Level 5, QQ Block, QEII Medical Centre, 6 Verdun Street, Nedlands, WA, 6009, Australia. bruce.robinson@uwa.edu.au.; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. bruce.robinson@uwa.edu.au.; Centre for Respiratory Health, University of Western Australia, Nedlands, WA, Australia. bruce.robinson@uwa.edu.au., Waddell N; Medical Genomics, Clinical Genomics and Genome Informatics Groups, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia. nic.waddell@qimrberghofer.edu.au.
المصدر: Genome medicine [Genome Med] 2022 May 30; Vol. 14 (1), pp. 58. Date of Electronic Publication: 2022 May 30.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101475844 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-994X (Electronic) Linking ISSN: 1756994X NLM ISO Abbreviation: Genome Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central
مواضيع طبية MeSH: Lung Neoplasms*/genetics , Mesothelioma*/genetics , Mesothelioma, Malignant* , Pleural Neoplasms*/genetics , Pleural Neoplasms*/pathology, Genomics ; Humans ; Tumor Microenvironment/genetics
مستخلص: Background: Malignant pleural mesothelioma (MPM) has a poor overall survival with few treatment options. Whole genome sequencing (WGS) combined with the immune features of MPM offers the prospect of identifying changes that could inform future clinical trials.
Methods: We analysed somatic mutations from 229 MPM samples, including previously published data and 58 samples that had undergone WGS within this study. This was combined with RNA-seq analysis to characterize the tumour immune environment.
Results: The comprehensive genome analysis identified 12 driver genes, including new candidate genes. Whole genome doubling was a frequent event that correlated with shorter survival. Mutational signature analysis revealed SBS5/40 were dominant in 93% of samples, and defects in homologous recombination repair were infrequent in our cohort. The tumour immune environment contained high M2 macrophage infiltrate linked with MMP2, MMP14, TGFB1 and CCL2 expression, representing an immune suppressive environment. The expression of TGFB1 was associated with overall survival. A small subset of samples (less than 10%) had a higher proportion of CD8 T cells and a high cytolytic score, suggesting a 'hot' immune environment independent of the somatic mutations.
Conclusions: We propose accounting for genomic and immune microenvironment status may influence therapeutic planning in the future.
(© 2022. The Author(s).)
References: PLoS One. 2013 Nov 08;8(11):e74380. (PMID: 24250782)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Nat Commun. 2021 Mar 19;12(1):1751. (PMID: 33741915)
Nature. 2020 Feb;578(7793):94-101. (PMID: 32025018)
Mol Oncol. 2020 Jun;14(6):1207-1223. (PMID: 32083805)
Neoplasia. 2019 Feb;21(2):247-256. (PMID: 30660076)
BMC Cancer. 2019 Jan 30;19(1):108. (PMID: 30700254)
Genome Biol. 2016 Feb 22;17:31. (PMID: 26899170)
Ann Oncol. 2015 Jan;26(1):64-70. (PMID: 25319062)
Lancet. 2021 Jan 30;397(10272):375-386. (PMID: 33485464)
Nat Commun. 2019 Mar 18;10(1):1245. (PMID: 30886153)
J Thorac Oncol. 2016 Oct;11(10):1765-73. (PMID: 27418105)
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947. (PMID: 30371878)
Genome Biol. 2019 Oct 21;20(1):213. (PMID: 31639029)
Science. 2018 Feb 16;359(6377):801-806. (PMID: 29301960)
Oncoimmunology. 2019 Nov 3;9(1):1684713. (PMID: 32002298)
Virchows Arch. 2019 Jan;474(1):3-12. (PMID: 30368555)
Genome Biol. 2011;12(4):R41. (PMID: 21527027)
Lancet Oncol. 2020 Sep;21(9):1213-1223. (PMID: 32888453)
Sci Rep. 2021 Oct 8;11(1):20059. (PMID: 34625620)
Oncotarget. 2016 Aug 9;7(32):52294-52306. (PMID: 27418133)
Cell Commun Signal. 2020 May 29;18(1):82. (PMID: 32471499)
Cell. 2021 Feb 4;184(3):596-614.e14. (PMID: 33508232)
Nature. 2015 May 28;521(7553):489-94. (PMID: 26017449)
Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795)
Nat Commun. 2019 Jul 18;10(1):3163. (PMID: 31320640)
Genome Res. 2010 Sep;20(9):1297-303. (PMID: 20644199)
Clin Cancer Res. 2016 Aug 1;22(15):3764-73. (PMID: 26957554)
Nat Genet. 2020 Feb;52(2):208-218. (PMID: 32015527)
Cell. 2015 Jan 15;160(1-2):48-61. (PMID: 25594174)
JTO Clin Res Rep. 2021 Sep 17;2(10):100231. (PMID: 34661178)
Nature. 2015 Feb 26;518(7540):495-501. (PMID: 25719666)
Nature. 2016 May 02;534(7605):47-54. (PMID: 27135926)
PLoS One. 2012;7(9):e45835. (PMID: 23049875)
Nature. 2014 Jan 23;505(7484):495-501. (PMID: 24390350)
Clin Cancer Res. 2020 Jul 15;26(14):3819-3830. (PMID: 32317288)
Pathology. 2013 Jan;45(1):44-8. (PMID: 23222247)
Lancet Oncol. 2011 Aug;12(8):763-72. (PMID: 21723781)
Genome Med. 2019 Mar 26;11(1):18. (PMID: 30914057)
Nat Commun. 2018 Aug 17;9(1):3292. (PMID: 30120226)
Nat Genet. 2015 Jun;47(6):668-71. (PMID: 25938944)
Semin Cancer Biol. 2008 Oct;18(5):349-55. (PMID: 18467122)
Pathobiology. 2020;87(3):208-216. (PMID: 32369821)
Oncogene. 2014 Jul 10;33(28):3748-52. (PMID: 23975423)
Thorax. 2003 Mar;58(3):198-203. (PMID: 12612292)
Nat Genet. 2016 Apr;48(4):407-16. (PMID: 26928227)
Genome Med. 2019 Feb 18;11(1):8. (PMID: 30777124)
Cancer Treat Rev. 2020 Nov;90:102091. (PMID: 32877777)
J Thorac Oncol. 2019 Feb;14(2):276-287. (PMID: 30316012)
J Mol Diagn. 2016 Jan;18(1):75-83. (PMID: 26607775)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
Genes Chromosomes Cancer. 2021 May;60(5):314-331. (PMID: 33222322)
Lancet Oncol. 2017 Aug;18(8):1009-1021. (PMID: 28694034)
Oncoimmunology. 2013 Aug 1;2(8):e26218. (PMID: 24179709)
Ind Health. 2007 Jun;45(3):379-87. (PMID: 17634686)
Ann Oncol. 2019 Jan 1;30(1):44-56. (PMID: 30395155)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Cancer Res. 2015 Jan 15;75(2):264-9. (PMID: 25488749)
Nat Genet. 2011 Jun 05;43(7):668-72. (PMID: 21642991)
Cancer Res. 1997 Aug 1;57(15):3200-7. (PMID: 9242450)
Cancer Discov. 2018 Dec;8(12):1548-1565. (PMID: 30322867)
J Thorac Oncol. 2018 Jan;13(1):124-133. (PMID: 29079455)
J Immunol. 2017 Nov 1;199(9):3360-3368. (PMID: 28978689)
Trials. 2018 Apr 18;19(1):233. (PMID: 29669604)
Lung Cancer. 2020 Jan;139:124-132. (PMID: 31778960)
Oncotarget. 2017 Dec 1;8(69):113673-113686. (PMID: 29371938)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
Br J Ind Med. 1960 Oct;17:260-71. (PMID: 13782506)
Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943)
Genome Med. 2016 Jan 29;8(1):11. (PMID: 26825632)
Nature. 2017 May 11;545(7653):175-180. (PMID: 28467829)
Mol Cancer. 2019 Aug 23;18(1):128. (PMID: 31443694)
Nat Genet. 2019 Feb;51(2):202-206. (PMID: 30643254)
Genome Biol. 2016 Jun 16;17(1):128. (PMID: 27311963)
Bioinformatics. 2014 Dec 1;30(23):3310-6. (PMID: 25143287)
Nat Med. 2017 Apr;23(4):517-525. (PMID: 28288110)
فهرسة مساهمة: Keywords: Immunotherapy; Malignant pleural mesothelioma; Mutational signatures; RNA sequencing; Tumour micro-environment; Whole genome sequencing
تواريخ الأحداث: Date Created: 20220531 Date Completed: 20220602 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9150319
DOI: 10.1186/s13073-022-01060-8
PMID: 35637530
قاعدة البيانات: MEDLINE
الوصف
تدمد:1756-994X
DOI:10.1186/s13073-022-01060-8